PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Graves' disease

Drugs in development · updated 30 October 2026

Graves' disease: drugs in development

As of 30 October 2026 there are 16 active clinical trials (recruiting or ongoing, phases I–III) on 13 drugs for Graves' disease. 9 are experimental, that is not yet approved in the United States.

16Active trials
9Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BHV-1300II–III3NCT07901244
LinsitinibIII1NCT07753603
IMVT-1402II3NCT07018323
FelzartamabII1NCT07722546
TOUR006 -II1NCT06088979
ETHY-001I1NCT07885605
GenSci098I1NCT07286656
MER511I1NCT07305818
REGN24493I1NCT07861152

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
AtorvastatinLipitor, Atorvaliq®II1NCT07883356
ErgocalciferolDrisdol®II1NCT07369063
MethimazoleTapazole®II1NCT07369063
RilzabrutinibWayrilz®II1NCT06984627

Sorted by most advanced phase and number of active trials.

All 13 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006111 “Graves Disease”.

ItalianoFrançaisDeutsch